GSK (GSK) Stock Analysis & Winston Score

GSK plc is a large British pharmaceutical company that makes prescription medicines, vaccines, and specialty health products. Its key products include the HIV treatment Dovato, the respiratory drug Nucala, and the shingles vaccine Shingrix, which is one of the best-selling vaccines in the world. GSK sells primarily to hospitals, pharmacies, governments, and health systems across both wealthy and developing nations. GSK earns money by selling branded drugs and vaccines, which carry high margins — reflected in its gross margin above 70%. The company operates globally, with major revenue coming from the United States, Europe, and international markets, and generates roughly $30 billion in annual sales. Its moat comes from patents, deep regulatory expertise, and a large vaccine manufacturing network that is difficult to replicate. The biggest risk GSK faces is patent expiration on key drugs, which allows cheaper generic competitors to enter and erode revenue over time.